This research shows novel α-glucosidase inhibitors improve postprandial hyperglycemia in T2DM, suggesting a new approach for diabetes management.
Type 2 diabetes mellitus (T2DM) remains a global health challenge, prompting the development of novel α-glucosidase inhibitors (AGIs) to regulate postprandial hyperglycemia. This study reports the design, synthesis, and evaluation of indole-based Schiff base derivatives (4a–4j) bearing a fixed methoxy group at the C5 position. This substitution was strategically introduced to enhance lipophilicity, electronic delocalization, and π-stacking within the enzyme active site. Among the series, compound 4g (3-bromophenyl) exhibited the highest inhibitory activity (IC50 = 10.89 µM), outperforming the clinical reference acarbose (IC50 = 48.95 µM). Mechanistic support from Density Functional Theory (DFT), molecular electrostatic potential (MEP) mapping, molecular dynamics simulations, and CNN-based docking revealed that 4g engages in stable hydrogen bonding and π–π interactions with key residues (Asp327, Asp542, Phe649). In silico ADMET predictions indicated favorable pharmacokinetic properties. Together, these results establish C5–methoxy substitution as a viable strategy to enhance α-glucosidase inhibition in indole-based scaffolds.
No takes yet. Share an insight, caveat, or question.
Bhagwat et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: